390 related articles for article (PubMed ID: 27083495)
1. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
Mahalatchimy A
Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
[TBL] [Abstract][Full Text] [Related]
2. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
3. The legal landscape for advanced therapies: material and institutional implementation of European Union rules in France and the United Kingdom.
Mahalatchimy A; Rial-Sebbag E; Tournay V; Faulkner A
J Law Soc; 2012; 39(1):131-49. PubMed ID: 22530249
[TBL] [Abstract][Full Text] [Related]
4. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
5. Market access pathways for cell therapies in France.
Rémuzat C; Toumi M; Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
[TBL] [Abstract][Full Text] [Related]
6. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
7. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
8. The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics.
Mahalatchimy A; Faulkner A
Regen Med; 2017 Sep; 12(6):611-622. PubMed ID: 28972450
[TBL] [Abstract][Full Text] [Related]
9. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios.
Gress S; Niebuhr D; May U; Wasem J
Pharmacoeconomics; 2007; 25(6):443-54. PubMed ID: 17523750
[TBL] [Abstract][Full Text] [Related]
10. The UK relative to other single payer-dominated healthcare markets for regenerative medicine therapies.
Rose JB; Williams DJ
Regen Med; 2012 May; 7(3):429-38. PubMed ID: 22594333
[TBL] [Abstract][Full Text] [Related]
11. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.
Bubela T; McCabe C; Archibald P; Atkins H; Bradshaw SE; Kefalas P; Mujoomdar M; Packer C; Piret J; Raxworthy M; Soares M; Viswanathan S
Regen Med; 2015; 10(7):897-911. PubMed ID: 26565607
[TBL] [Abstract][Full Text] [Related]
12. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
13. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
14. Opening the gateways to market and adoption of regenerative medicine? The UK case in context.
Faulkner A
Regen Med; 2016 Apr; 11(3):321-30. PubMed ID: 27035398
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan.
Oye KA; Eichler HG; Hoos A; Mori Y; Mullin TM; Pearson M
Clin Pharmacol Ther; 2016 Dec; 100(6):626-632. PubMed ID: 27618128
[TBL] [Abstract][Full Text] [Related]
16. [A proposal for reforming psychologists' training in France and in the European Union].
Bouchard JP
Encephale; 2009 Feb; 35(1):18-24. PubMed ID: 19250989
[TBL] [Abstract][Full Text] [Related]
17. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
[TBL] [Abstract][Full Text] [Related]
18. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement.
Cho E; Yoo SL; Kang Y; Lee JH
Regen Med; 2020 Apr; 15(4):1550-1560. PubMed ID: 32356480
[TBL] [Abstract][Full Text] [Related]
19. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
Plagnol AC; Rowley E; Martin P; Livesey F
Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
[TBL] [Abstract][Full Text] [Related]
20. Innovative regenerative medicines in the EU: a better future in evidence?
Corbett MS; Webster A; Hawkins R; Woolacott N
BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
